新型全自动抗IA2抗体ELISA在1型糖尿病中的性能评估
评估新型桥式抗IA2 ELISA(Euroimmun)的分析与临床性能,该试剂符合欧洲IVDR并适配全自动平台。研究显示批内/批间CV≤3.2%,线性范围10-2000 IU/mL,临床T1D队列灵敏度53.8%(新诊断56.5%),IASP样本灵敏度76.0%,非T1D对照特异性98.4%,与前一版本ELISA几乎完全一致(94.7%,κ=0.873)。
要点
- 新型抗IA2 ELISA精密度良好,CV≤3.2%,线性范围10-2000 IU/mL,不受溶血、脂血、黄疸干扰。
- 临床T1D队列灵敏度53.8%,新诊断患者56.5%,IASP病例样本灵敏度76.0%,非T1D对照特异性98.4%。
- 与前一版本ELISA一致性94.7%(κ=0.873),与放射免疫法一致性82.4-83.8%(κ≥0.637)。
核心结论
- 新型抗IA2 ELISA兼具良好的分析和诊断性能,配合全自动流程可实现标准化端到端处理,适合高通量常规诊断。
研究设计与样本
- 分析性能评估包括精密度、检测能力、线性和干扰研究。
- 诊断准确性测试及方法学比对使用T1D患者(诊断中位年龄11岁,糖尿病中位病程4年)、成人隐匿性自身免疫糖尿病、Addison病患者血清,以及非T1D对照和IASP样本。
- 与前一版本ELISA和Medipan CentAK抗IA2 M放射免疫法进行方法学比较。
主要发现
- 批内/批间不精密度CV≤3.2%,检测限在低IU/mL范围,线性范围10-2000 IU/mL,溶血、脂血、黄疸样本无干扰。
- 临床T1D队列灵敏度53.8%,新诊断患者56.5%,IASP病例样本灵敏度76.0%,非T1D对照特异性98.4%。
- 与前一版本ELISA一致性94.7%(κ=0.873),与放射免疫法一致性82.4-83.8%(κ≥0.637),且ELISA识别出更多抗IA2阳性T1D样本。
关键数值与推荐
- 批内/批间CV≤3.2%。
- 线性范围10-2000 IU/mL。
- 临床T1D队列灵敏度53.8%(新诊断56.5%),IASP病例样本灵敏度76.0%,非T1D对照特异性98.4%。
- 与前一版本ELISA一致性94.7%(κ=0.873),与放射免疫法一致性82.4-83.8%(κ≥0.637)。
临床怎么用
- 该全自动ELISA适用于高通量常规实验室开展抗IA2抗体标准化检测。
- 方法学比对显示与放射免疫法和前一版本ELISA高度一致,可支持临床诊断和风险分层。
局限性
- 需在更大规模、人群代表性队列中进行前瞻性验证,以评估其用于大规模筛查的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoantibodies to insulinoma-associated antigen 2 (IA2) are well-established biomarkers of islet autoimmunity, supporting the diagnosis and risk stratification of type 1 diabetes (T1D). This study presents the analytical and clinical evaluation of a newly developed bridge-type Anti-IA2 ELISA (Euroimmun), which is CE-marked under the European In Vitro Diagnostic Regulation (IVDR) and compatible with fully automated processing platforms. The analytical performance was assessed through precision, detection capability, linearity, and interference studies. Diagnostic accuracy testing and method comparison with the predecessor ELISA and the Medipan CentAK anti-IA2 M radioimmunoassay were performed using serum samples from patients with T1D (median age at diagnosis: 11 years; median diabetes duration: 4 years), latent autoimmune diabetes in adults, or Addison's disease, as well as samples from non-T1D control groups and the Islet Autoantibody Standardization Program (IASP). The assay demonstrated low intra-/inter-lot imprecision (CVs ≤ 3.2%), detection limits in the low IU/mL range, linearity over the measuring range (10-2000 IU/mL), and no interference from hemolytic, lipemic, or icteric sample conditions. Sensitivity was 53.8% in the clinical T1D cohort (56.5% in newly diagnosed patients), and 76.0% in IASP case samples. Specificity in non-T1D controls reached 98.4%. Agreement with the predecessor ELISA was almost perfect (94.7%; κ = 0.873). Compared with the radioimmunoassay, substantial agreement (82.4-83.8%; κ ≥ 0.637) was observed, and the ELISA identified more anti-IA2-positive T1D samples. In conclusion, the new Anti-IA2 ELISA combines strong analytical and diagnostic performance with a fully automated workflow enabling standardized end-to-end processing. These features support implementation in high-throughput routine diagnostics. Prospective validation in larger and population-representative cohorts is warranted to further assess the assay's suitability for potential future use in large-scale screening aimed at improving early detection and risk assessment in autoimmune diabetes.
引用
- Lehmann M, Hò GT, Augstein P, et al. Performance assessment of a novel fully automated ELISA for anti-IA2 autoantibody detection in type 1 diabetes. Clin Chim Acta. 2026. PMID: 42822623. doi:10.1016/j.cca.2026.122866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。